Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Research & Development (2023 - 2025)

CG Oncology filings provide 3 years of Research & Development readings, the most recent being $30.0 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 11.78% to $30.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $116.6 million, a 42.07% increase, with the full-year FY2025 number at $116.6 million, up 42.07% from a year prior.
  • Research & Development hit $30.0 million in Q4 2025 for CG Oncology, up from $27.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $31.3 million in Q2 2025 to a low of $7.8 million in Q1 2023.
  • Median Research & Development over the past 3 years was $19.0 million (2024), compared with a mean of $20.4 million.
  • Biggest five-year swings in Research & Development: skyrocketed 119.46% in 2024 and later increased 11.78% in 2025.
  • CG Oncology's Research & Development stood at $16.3 million in 2023, then surged by 64.01% to $26.8 million in 2024, then grew by 11.78% to $30.0 million in 2025.
  • The last three reported values for Research & Development were $30.0 million (Q4 2025), $27.9 million (Q3 2025), and $31.3 million (Q2 2025) per Business Quant data.